Financials in USD. Standardized financial statements.
A compact view of how Magenta Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $2.04M | $6.24M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | -67.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Margin? | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $179.97M | $108.10M | $80.90M | $74.69M | $78.70M | $82.97M | $59.96M | $35.73M | $9.27M |
| Operating Income? | -$177.93M | -$101.86M | -$80.90M | -$74.69M | -$78.70M | -$82.97M | -$59.96M | -$35.73M | -$9.27M |
| EBITDA? | -$177.93M | -$101.86M | -$78.98M | -$74.69M | -$78.70M | -$82.97M | -$59.96M | -$35.12M | -$9.26M |
| Income Before Tax | -$162.34M | -$84.97M | -$76.46M | -$71.14M | -$74.94M | -$76.77M | -$57.52M | -$35.49M | -$9.43M |
| Income Tax Expense | $0 | $0 | -$4.44M | -$5.58M | -$5.74M | -$8.04M | $0 | $236,000 | $0 |
| Net Income? | -$162.34M | -$84.97M | -$72.02M | -$65.56M | -$69.19M | -$68.73M | -$57.52M | -$35.49M | -$9.43M |
| EPS? | $0.00 | $-21.75 | $-23.05 | $-1.12 | $-1.43 | $-1.75 | $-59.42 | $-1.65 | $-0.44 |
| Diluted EPS? | $0.00 | $-21.75 | $-23.05 | $-1.12 | $-1.43 | $-1.75 | $-59.42 | $-1.65 | $-0.44 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality